-Annual Revenue rose 26%, in the last year to Rs 1,200 Crores. Its sector's average revenue growth for the last fiscal year was 8.4%.
-Annual Net Profit rose 156.2% in the last year to Rs 163.5 Crores. Its sector's average net profit growth for the last fiscal year was 1.3%
-Price to Earning Ratio is 24.9, lower than its sector PE ratio of 42.6.
-FII/FPI have increased holdings from 18.14% to 20.19% in Jun 2023 qtr.
-Mutual Funds have increased holdings from 0.99% to 1.57% in Jun 2023 qtr.
Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.
Their products are exported to more than 35 countries including Germany, Italy, Switzerland, the UK and the Netherlands.
-Annual Net Profit rose 156.2% in the last year to Rs 163.5 Crores. Its sector's average net profit growth for the last fiscal year was 1.3%
-Price to Earning Ratio is 24.9, lower than its sector PE ratio of 42.6.
-FII/FPI have increased holdings from 18.14% to 20.19% in Jun 2023 qtr.
-Mutual Funds have increased holdings from 0.99% to 1.57% in Jun 2023 qtr.
Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.
Their products are exported to more than 35 countries including Germany, Italy, Switzerland, the UK and the Netherlands.
Trade ativo
Nota
Target 1 and counting - Approx 20% achieved so farNota
Target 2 AchievedTrade fechado: objetivo atingido
35% Achieved in about 4-5 Weeks
Aviso legal
As informações e publicações não devem ser e não constituem conselhos ou recomendações financeiras, de investimento, de negociação ou de qualquer outro tipo, fornecidas ou endossadas pela TradingView. Leia mais em Termos de uso.
Aviso legal
As informações e publicações não devem ser e não constituem conselhos ou recomendações financeiras, de investimento, de negociação ou de qualquer outro tipo, fornecidas ou endossadas pela TradingView. Leia mais em Termos de uso.